AMICUS THERAPEUTICS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred financing
Depreciation and amortization
Stock-based compensation
Loss on exchange of convertible notes
Loss on extinguishment of debt
Non-cash changes in the fair value of contingent consideration payable
Foreign currency remeasurement loss
Non-cash deferred taxes
Other
Asset impairment charges and other write-offs
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable, accrued expenses, and other current liabilities
Other non-current assets and liabilities
Deferred reimbursements
Payment of contingent consideration

Net cash provided by (used in) operating activities
Investing activities
Sale and redemption of marketable securities
Purchases of marketable securities
Capital expenditures
Proceeds from sale of assets
Net cash (used in) provided by investing activities
Financing activities
Proceeds from issuance of common stock, net of issuance costs
Proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs
Proceeds from equity financing, net of issuance costs
Withholding taxes paid on vested restricted stock units
Proceeds from stock options exercised, net
Proceeds from warrants exercised, net
Payment of long-term debt
Proceeds from long-term debt, net of issuance costs
Payment of contingent consideration
Payment of finance leases
Payments of employee withholding taxes related to restricted stock unit vesting
Proceeds from termination of capped call confirmations
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents, and restricted cash
Net increase (decrease) in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at the beginning of the year
Cash, cash equivalents, and restricted cash at the end of the year
Supplemental disclosures of cash flow information
Tenant improvements paid through lease incentive
Cash paid during the period for interest
Contingent consideration paid in shares
Cashless exercise of warrants
Capital expenditures unpaid at the end of period
Cash paid for income taxes

Comments